AAAAI Issues Statement in Response to the Announcement of a Generic Epinephrine Autoinjector

Share Article

"We implore all parties involved with the manufacturing, approval and distribution of this alternative, as well as any other equivalent product in development, to make it available as soon as possible."

News Image
. . . Skyrocketing costs for autoinjectable epinephrine products place an unacceptable burden on our patients, and we vigorously support all efforts to address this urgent issue as quickly as possible.

The American Academy of Allergy, Asthma & Immunology (AAAAI) has issued the following statement in response to today’s announcement that a generic epinephrine autoinjector will be made available:

The AAAAI welcomes the announcement from Mylan this morning that they will soon have a generic epinephrine autoinjector available at a lower cost (approximately $300 for a two-pack) than EpiPen. We implore all parties involved with the manufacturing, approval and distribution of this alternative, as well as any other equivalent product in development, to make it available as soon as possible. Improving patient outcomes requires this shared commitment to patient access.

“Patients with high risk for life-threatening anaphylaxis, including those with food allergy and stinging insect allergy, require a ready supply of epinephrine via autoinjectors. There is no reasonable alternative to this medication for these people, who may die if they do not have injectable epinephrine immediately available at home and work (or school) when anaphylaxis occurs. Skyrocketing costs for autoinjectable epinephrine products place an unacceptable burden on our patients, and we vigorously support all efforts to address this urgent issue as quickly as possible," said AAAAI Executive Vice President Thomas B. Casale, MD, FAAAAI. “The AAAAI appreciates the support of other medical societies, patient advocacy organizations, and Congressional efforts to address this medical crisis for our patients.”

The AAAAI represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 6,900 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

Share article on social media or email:

View article via:

Pdf Print